On June 5, Novartis rose 3.13% in regular trading, trading at $148.185/share, with trading volume of $275 million. The move was driven by positive late-stage clinical trial results for its core product Cosentyx and broader strength across the pharmaceutical sector.

Novartis disclosed new Phase 3 data showing Cosentyx achieved a statistically significant and clinically meaningful difference in sustained remission rates in polymyalgia rheumatica (PMR) compared to the control group. Additionally, the company presented strong early-stage clinical data at the ASCO annual meeting for a novel radioligand therapy targeting prostate cancer, reinforcing growth expectations for its pipeline. The dual catalysts from Cosentyx and its oncology portfolio bolstered investor confidence.

Within the Pharmacy sector, the overall sector showed strength. Among individual stocks, Merck up 4.68%, Novo-Nordisk up 4.30%, Eli Lilly up 4.04%, Johnson & Johnson up 2.26%, Pfizer up 1.48%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)